Pricing By Indication Takes Hold, Despite Hurdles

Indication-based drug pricing is one mechanism for pegging price to value. It will be tough to implement in the US without systemic change, but PBMs have plenty of incentives to make it work.

IV1701_IndicationPricing_1200x675

More from Market Access

More from In Vivo